VivoSim Labs, INC. VIVS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-75.52
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $144,000 | -$2.5M | — | -$9.5M | $10.5M |
| 2024 | $109,000 | -$14.7M | — | -$14.7M | $3.6M |
| 2023 | $370,000 | -$17.3M | — | -$12.8M | $15.3M |
| 2022 | $1.5M | -$11.4M | — | -$8.9M | $30.2M |
| 2021 | $0 | -$16.8M | — | -$13.7M | $39.2M |
| 2020 | $2.2M | -$18.7M | — | -$14.9M | $26.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Cohen Douglas Jay | director | 2026-01-27 | Grant | 15,000 | — |
| Murphy Keith | EXECUTIVE CHAIRMAN | 2026-01-27 | Grant | 15,000 | — |
| Milhous Alison Tjosvold | director | 2026-01-27 | Grant | 15,000 | — |
| Gobel David | director | 2026-01-27 | Grant | 15,000 | — |
| STERN ADAM K | director | 2026-01-27 | Grant | 15,000 | — |
| Gobel David | director | 2025-11-17 | Sell | 3,266 | $2.24 |
| Gobel David | director | 2024-08-07 | Grant | 19,607 | — |
| Cohen Douglas Jay | director | 2024-08-07 | Grant | 19,607 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -75.52 (distress)
- Working capital / assets 0.573
- Retained earnings / assets -23.355
- EBIT / assets -0.861
- Equity / liabilities 2.523
Source: SEC EDGAR filings · CIK 0001497253 · as of 2025-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.